Padsevonil

Last updated

Padsevonil
Padsevonil v2.svg
Clinical data
Other namesUCB-0942; UCB0942; UCB1415943-000
Routes of
administration 		Oral [1]
Drug class Synaptic vesicle glycoprotein 2A (SV2A) ligand [2]
Identifiers
  • (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C14H14ClF5N4O2S
Molar mass 432.79 g·mol−1
3D model (JSmol)
  • COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl
  • InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1
  • Key:DCXFIOLWWRXEQH-SSDOTTSWSA-N

Padsevonil (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name, JAN Tooltip Japanese Accepted Name; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy. [1] [3] [2] It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam. [2] However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam. [2] In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C). [2] The drug is being developed by UCB. [1] [3] As of November 2023, it is in phase 2 clinical trials. [1] [3]

References

  1. 1 2 3 4 "Padsevonil". AdisInsight. 5 November 2023. Retrieved 26 February 2025.
  2. 1 2 3 4 5 Wu PP, Cao BR, Tian FY, Gao ZB (May 2024). "Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil". Neuroscience Bulletin. 40 (5): 594–608. doi:10.1007/s12264-023-01138-2. PMC   11127901 . PMID   37897555.
  3. 1 2 3 "Delving into the Latest Updates on Padsevonil with Synapse". Synapse. 8 February 2025. Retrieved 26 February 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.